Margulies I - Search Results

1

Hairy cell leukemia, a B-cell neoplasm that is particularly sensitive to the cytotoxic effect of anti-Tac(Fv)-PE38 (LMB-2).

Robbins DH, Margulies I, Stetler-Stevenson M, Kreitman RJ. Robbins DH, et al. Among authors: margulies i. Clin Cancer Res. 2000 Feb;6(2):693-700. Clin Cancer Res. 2000. PMID: 10690555

2

Improved cytotoxic activity toward cell lines and fresh leukemia cells of a mutant anti-CD22 immunotoxin obtained by antibody phage display.

Salvatore G, Beers R, Margulies I, Kreitman RJ, Pastan I. Salvatore G, et al. Among authors: margulies i. Clin Cancer Res. 2002 Apr;8(4):995-1002. Clin Cancer Res. 2002. PMID: 11948105

3

Minimal residual disease in hairy cell leukemia patients assessed by clone-specific polymerase chain reaction.

Arons E, Margulies I, Sorbara L, Raffeld M, Stetler-Stevenson M, Pastan I, Kreitman RJ. Arons E, et al. Among authors: margulies i. Clin Cancer Res. 2006 May 1;12(9):2804-11. doi: 10.1158/1078-0432.CCR-05-2315. Clin Cancer Res. 2006. PMID: 16675574

4

PRAME expression in hairy cell leukemia.

Arons E, Suntum T, Margulies I, Yuan C, Stetler-Stevenson M, Kreitman RJ. Arons E, et al. Among authors: margulies i. Leuk Res. 2008 Sep;32(9):1400-6. doi: 10.1016/j.leukres.2007.12.010. Epub 2008 Mar 4. Leuk Res. 2008. PMID: 18295331 Free PMC article.

5

Soluble CD22 as a tumor marker for hairy cell leukemia.

Matsushita K, Margulies I, Onda M, Nagata S, Stetler-Stevenson M, Kreitman RJ. Matsushita K, et al. Among authors: margulies i. Blood. 2008 Sep 15;112(6):2272-7. doi: 10.1182/blood-2008-01-131987. Epub 2008 Jul 2. Blood. 2008. PMID: 18596230 Free PMC article.

6

Phase II trial of recombinant immunotoxin RFB4(dsFv)-PE38 (BL22) in patients with hairy cell leukemia.

Kreitman RJ, Stetler-Stevenson M, Margulies I, Noel P, Fitzgerald DJ, Wilson WH, Pastan I. Kreitman RJ, et al. Among authors: margulies i. J Clin Oncol. 2009 Jun 20;27(18):2983-90. doi: 10.1200/JCO.2008.20.2630. Epub 2009 May 4. J Clin Oncol. 2009. PMID: 19414673 Free PMC article. Clinical Trial.

7

Responses in refractory hairy cell leukemia to a recombinant immunotoxin.

Kreitman RJ, Wilson WH, Robbins D, Margulies I, Stetler-Stevenson M, Waldmann TA, Pastan I. Kreitman RJ, et al. Among authors: margulies i. Blood. 1999 Nov 15;94(10):3340-8. Blood. 1999. PMID: 10552943 Free article. Clinical Trial.

8

Cytotoxic activity of disulfide-stabilized recombinant immunotoxin RFB4(dsFv)-PE38 (BL22) toward fresh malignant cells from patients with B-cell leukemias.

Kreitman RJ, Margulies I, Stetler-Stevenson M, Wang QC, FitzGerald DJ, Pastan I. Kreitman RJ, et al. Among authors: margulies i. Clin Cancer Res. 2000 Apr;6(4):1476-87. Clin Cancer Res. 2000. PMID: 10778980

9

Anti-tumor activity of K1-LysPE38QQR, an immunotoxin targeting mesothelin, a cell-surface antigen overexpressed in ovarian cancer and malignant mesothelioma.

Hassan R, Viner JL, Wang QC, Margulies I, Kreitman RJ, Pastan I. Hassan R, et al. Among authors: margulies i. J Immunother. 2000 Jul-Aug;23(4):473-9. doi: 10.1097/00002371-200007000-00011. J Immunother. 2000. PMID: 10916757

10

A protease-resistant immunotoxin against CD22 with greatly increased activity against CLL and diminished animal toxicity.

Weldon JE, Xiang L, Chertov O, Margulies I, Kreitman RJ, FitzGerald DJ, Pastan I. Weldon JE, et al. Among authors: margulies i. Blood. 2009 Apr 16;113(16):3792-800. doi: 10.1182/blood-2008-08-173195. Epub 2008 Nov 6. Blood. 2009. PMID: 18988862 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

58 results

Search Page

Filters